ParkinsonCanadaV1, PubMed, Corpus, bibRecord, 001318

Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.

Identifieur interne : 001318 ( PubMed/Corpus ); précédent : 001317; suivant : 001319

Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.

Auteurs : Gerlinde A. Metz ; Dionne M. Piecharka ; Jeffrey A. Kleim ; Ian Q. Whishaw

Source :

Brain research [ 0006-8993 ] ; 2004.

RBID : pubmed:15476704

English descriptors

KwdEn :
- Analysis of Variance, Animals, Apomorphine (pharmacology), Behavior, Animal, Brain (physiopathology), Brain (radiation effects), Brain Mapping, Cell Count, Disease Models, Animal, Dopamine (deficiency), Electric Stimulation (methods), Forelimb (innervation), Forelimb (physiopathology), Functional Laterality (physiology), Immunohistochemistry (methods), Male, Movement (drug effects), Movement (physiology), Oxidopamine, Parkinson Disease (etiology), Parkinson Disease (metabolism), Parkinson Disease (physiopathology), Psychomotor Performance (physiology), Rats, Rats, Long-Evans, Rotation, Sympatholytics, Tyrosine 3-Monooxygenase (metabolism).
MESH :
- chemical , deficiency : Dopamine.
- chemical , metabolism : Tyrosine 3-Monooxygenase.
- chemical , pharmacology : Apomorphine.
- drug effects : Movement.
- etiology : Parkinson Disease.
- innervation : Forelimb.
- metabolism : Parkinson Disease.
- methods : Electric Stimulation, Immunohistochemistry.
- physiology : Functional Laterality, Movement, Psychomotor Performance.
- physiopathology : Brain, Forelimb, Parkinson Disease.
- radiation effects : Brain.
- Analysis of Variance, Animals, Behavior, Animal, Brain Mapping, Cell Count, Disease Models, Animal, Male, Oxidopamine, Rats, Rats, Long-Evans, Rotation, Sympatholytics.

Abstract

The classic view of dopamine (DA) loss in Parkinson's disease is that it produces a functional deafferentation in striatal-cortical circuitry that, in turn, contributes to sensorimotor deficits. The present study examines this view in the rat by assessing how DA-depletion affects the intracortical microstimulation (ICMS) topographic representation of movement in the rostral and caudal motor areas of the motor cortex. The ICMS map is used as an index of motor cortex function because it has been shown to reflect motor function and experience. Groups of rats received no training or skilled reach training and were then given unilateral 6-hydroxydopamine (6-OHDA) or sham lesions of the nigrostriatal bundle to deplete nigrostriatal DA. Lesion success was confirmed by abnormalities in skilled reaching, by apomorphine-induced rotation, and by loss of DA neurons in the substantia nigra. The size and threshold of the motor map in naive and skilled reach trained DA-depleted rats were preserved. In addition, there was an increase in distal limb representation in the caudal forelimb area (CFA) in the DA-depleted rats suggesting a possible plastic response to the behavioral effects of DA-depletion. The presence of preserved size and modified map organization in DA-depleted rats is discussed in relation to the hypothesis that preserved motor cortex functionality despite DA loss underlies the spared motor abilities of DA-depleted rats.

DOI: 10.1016/j.brainres.2004.08.025
PubMed: 15476704

Links to Exploration step

pubmed:15476704

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.</title>
<author><name sortKey="Metz, Gerlinde A" sort="Metz, Gerlinde A" uniqKey="Metz G" first="Gerlinde A" last="Metz">Gerlinde A. Metz</name>
<affiliation><nlm:affiliation>Canadian Centre for Behavioural Neuroscience, University of Lethbridge, Lethbridge, AB, Canada, T1K 3M4, Canada gerlinde.metz@uleth.ca.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Piecharka, Dionne M" sort="Piecharka, Dionne M" uniqKey="Piecharka D" first="Dionne M" last="Piecharka">Dionne M. Piecharka</name>
</author>
<author><name sortKey="Kleim, Jeffrey A" sort="Kleim, Jeffrey A" uniqKey="Kleim J" first="Jeffrey A" last="Kleim">Jeffrey A. Kleim</name>
</author>
<author><name sortKey="Whishaw, Ian Q" sort="Whishaw, Ian Q" uniqKey="Whishaw I" first="Ian Q" last="Whishaw">Ian Q. Whishaw</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15476704</idno>
<idno type="pmid">15476704</idno>
<idno type="doi">10.1016/j.brainres.2004.08.025</idno>
<idno type="wicri:Area/PubMed/Corpus">001318</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">001318</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.</title>
<author><name sortKey="Metz, Gerlinde A" sort="Metz, Gerlinde A" uniqKey="Metz G" first="Gerlinde A" last="Metz">Gerlinde A. Metz</name>
<affiliation><nlm:affiliation>Canadian Centre for Behavioural Neuroscience, University of Lethbridge, Lethbridge, AB, Canada, T1K 3M4, Canada gerlinde.metz@uleth.ca.</nlm:affiliation>
</affiliation>
</author>
<author><name sortKey="Piecharka, Dionne M" sort="Piecharka, Dionne M" uniqKey="Piecharka D" first="Dionne M" last="Piecharka">Dionne M. Piecharka</name>
</author>
<author><name sortKey="Kleim, Jeffrey A" sort="Kleim, Jeffrey A" uniqKey="Kleim J" first="Jeffrey A" last="Kleim">Jeffrey A. Kleim</name>
</author>
<author><name sortKey="Whishaw, Ian Q" sort="Whishaw, Ian Q" uniqKey="Whishaw I" first="Ian Q" last="Whishaw">Ian Q. Whishaw</name>
</author>
</analytic>
<series><title level="j">Brain research</title>
<idno type="ISSN">0006-8993</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Analysis of Variance</term>
<term>Animals</term>
<term>Apomorphine (pharmacology)</term>
<term>Behavior, Animal</term>
<term>Brain (physiopathology)</term>
<term>Brain (radiation effects)</term>
<term>Brain Mapping</term>
<term>Cell Count</term>
<term>Disease Models, Animal</term>
<term>Dopamine (deficiency)</term>
<term>Electric Stimulation (methods)</term>
<term>Forelimb (innervation)</term>
<term>Forelimb (physiopathology)</term>
<term>Functional Laterality (physiology)</term>
<term>Immunohistochemistry (methods)</term>
<term>Male</term>
<term>Movement (drug effects)</term>
<term>Movement (physiology)</term>
<term>Oxidopamine</term>
<term>Parkinson Disease (etiology)</term>
<term>Parkinson Disease (metabolism)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Psychomotor Performance (physiology)</term>
<term>Rats</term>
<term>Rats, Long-Evans</term>
<term>Rotation</term>
<term>Sympatholytics</term>
<term>Tyrosine 3-Monooxygenase (metabolism)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="deficiency" xml:lang="en"><term>Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en"><term>Tyrosine 3-Monooxygenase</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Apomorphine</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Movement</term>
</keywords>
<keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="innervation" xml:lang="en"><term>Forelimb</term>
</keywords>
<keywords scheme="MESH" qualifier="metabolism" xml:lang="en"><term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Electric Stimulation</term>
<term>Immunohistochemistry</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Functional Laterality</term>
<term>Movement</term>
<term>Psychomotor Performance</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en"><term>Brain</term>
<term>Forelimb</term>
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="radiation effects" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Analysis of Variance</term>
<term>Animals</term>
<term>Behavior, Animal</term>
<term>Brain Mapping</term>
<term>Cell Count</term>
<term>Disease Models, Animal</term>
<term>Male</term>
<term>Oxidopamine</term>
<term>Rats</term>
<term>Rats, Long-Evans</term>
<term>Rotation</term>
<term>Sympatholytics</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The classic view of dopamine (DA) loss in Parkinson's disease is that it produces a functional deafferentation in striatal-cortical circuitry that, in turn, contributes to sensorimotor deficits. The present study examines this view in the rat by assessing how DA-depletion affects the intracortical microstimulation (ICMS) topographic representation of movement in the rostral and caudal motor areas of the motor cortex. The ICMS map is used as an index of motor cortex function because it has been shown to reflect motor function and experience. Groups of rats received no training or skilled reach training and were then given unilateral 6-hydroxydopamine (6-OHDA) or sham lesions of the nigrostriatal bundle to deplete nigrostriatal DA. Lesion success was confirmed by abnormalities in skilled reaching, by apomorphine-induced rotation, and by loss of DA neurons in the substantia nigra. The size and threshold of the motor map in naive and skilled reach trained DA-depleted rats were preserved. In addition, there was an increase in distal limb representation in the caudal forelimb area (CFA) in the DA-depleted rats suggesting a possible plastic response to the behavioral effects of DA-depletion. The presence of preserved size and modified map organization in DA-depleted rats is discussed in relation to the hypothesis that preserved motor cortex functionality despite DA loss underlies the spared motor abilities of DA-depleted rats.</div>
</front>
</TEI>
<pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">15476704</PMID>
<DateCreated><Year>2004</Year>
<Month>10</Month>
<Day>12</Day>
</DateCreated>
<DateCompleted><Year>2005</Year>
<Month>01</Month>
<Day>24</Day>
</DateCompleted>
<DateRevised><Year>2013</Year>
<Month>11</Month>
<Day>21</Day>
</DateRevised>
<Article PubModel="Print"><Journal><ISSN IssnType="Print">0006-8993</ISSN>
<JournalIssue CitedMedium="Print"><Volume>1026</Volume>
<Issue>1</Issue>
<PubDate><Year>2004</Year>
<Month>Nov</Month>
<Day>05</Day>
</PubDate>
</JournalIssue>
<Title>Brain research</Title>
<ISOAbbreviation>Brain Res.</ISOAbbreviation>
</Journal>
<ArticleTitle>Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.</ArticleTitle>
<Pagination><MedlinePgn>126-35</MedlinePgn>
</Pagination>
<Abstract><AbstractText>The classic view of dopamine (DA) loss in Parkinson's disease is that it produces a functional deafferentation in striatal-cortical circuitry that, in turn, contributes to sensorimotor deficits. The present study examines this view in the rat by assessing how DA-depletion affects the intracortical microstimulation (ICMS) topographic representation of movement in the rostral and caudal motor areas of the motor cortex. The ICMS map is used as an index of motor cortex function because it has been shown to reflect motor function and experience. Groups of rats received no training or skilled reach training and were then given unilateral 6-hydroxydopamine (6-OHDA) or sham lesions of the nigrostriatal bundle to deplete nigrostriatal DA. Lesion success was confirmed by abnormalities in skilled reaching, by apomorphine-induced rotation, and by loss of DA neurons in the substantia nigra. The size and threshold of the motor map in naive and skilled reach trained DA-depleted rats were preserved. In addition, there was an increase in distal limb representation in the caudal forelimb area (CFA) in the DA-depleted rats suggesting a possible plastic response to the behavioral effects of DA-depletion. The presence of preserved size and modified map organization in DA-depleted rats is discussed in relation to the hypothesis that preserved motor cortex functionality despite DA loss underlies the spared motor abilities of DA-depleted rats.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Metz</LastName>
<ForeName>Gerlinde A</ForeName>
<Initials>GA</Initials>
<AffiliationInfo><Affiliation>Canadian Centre for Behavioural Neuroscience, University of Lethbridge, Lethbridge, AB, Canada, T1K 3M4, Canada gerlinde.metz@uleth.ca.</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y"><LastName>Piecharka</LastName>
<ForeName>Dionne M</ForeName>
<Initials>DM</Initials>
</Author>
<Author ValidYN="Y"><LastName>Kleim</LastName>
<ForeName>Jeffrey A</ForeName>
<Initials>JA</Initials>
</Author>
<Author ValidYN="Y"><LastName>Whishaw</LastName>
<ForeName>Ian Q</ForeName>
<Initials>IQ</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList><PublicationType UI="D003160">Comparative Study</PublicationType>
<PublicationType UI="D016428">Journal Article</PublicationType>
<PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
</PublicationTypeList>
</Article>
<MedlineJournalInfo><Country>Netherlands</Country>
<MedlineTA>Brain Res</MedlineTA>
<NlmUniqueID>0045503</NlmUniqueID>
<ISSNLinking>0006-8993</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList><Chemical><RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D013565">Sympatholytics</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>8HW4YBZ748</RegistryNumber>
<NameOfSubstance UI="D016627">Oxidopamine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>EC 1.14.16.2</RegistryNumber>
<NameOfSubstance UI="D014446">Tyrosine 3-Monooxygenase</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>N21FAR7B4S</RegistryNumber>
<NameOfSubstance UI="D001058">Apomorphine</NameOfSubstance>
</Chemical>
<Chemical><RegistryNumber>VTD58H1Z2X</RegistryNumber>
<NameOfSubstance UI="D004298">Dopamine</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList><MeshHeading><DescriptorName UI="D000704" MajorTopicYN="N">Analysis of Variance</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001058" MajorTopicYN="N">Apomorphine</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001522" MajorTopicYN="N">Behavior, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001921" MajorTopicYN="N">Brain</DescriptorName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
<QualifierName UI="Q000528" MajorTopicYN="N">radiation effects</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D001931" MajorTopicYN="Y">Brain Mapping</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D002452" MajorTopicYN="N">Cell Count</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004298" MajorTopicYN="N">Dopamine</DescriptorName>
<QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D004558" MajorTopicYN="N">Electric Stimulation</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D005552" MajorTopicYN="N">Forelimb</DescriptorName>
<QualifierName UI="Q000294" MajorTopicYN="N">innervation</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007839" MajorTopicYN="N">Functional Laterality</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D007150" MajorTopicYN="N">Immunohistochemistry</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D009068" MajorTopicYN="N">Movement</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D016627" MajorTopicYN="N">Oxidopamine</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>
<QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
<QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D011597" MajorTopicYN="N">Psychomotor Performance</DescriptorName>
<QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D020318" MajorTopicYN="N">Rats, Long-Evans</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D012399" MajorTopicYN="N">Rotation</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D013565" MajorTopicYN="N">Sympatholytics</DescriptorName>
</MeshHeading>
<MeshHeading><DescriptorName UI="D014446" MajorTopicYN="N">Tyrosine 3-Monooxygenase</DescriptorName>
<QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2004</Year>
<Month>08</Month>
<Day>19</Day>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed"><Year>2004</Year>
<Month>10</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline"><Year>2005</Year>
<Month>1</Month>
<Day>26</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="entrez"><Year>2004</Year>
<Month>10</Month>
<Day>13</Day>
<Hour>9</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList><ArticleId IdType="pubmed">15476704</ArticleId>
<ArticleId IdType="pii">S0006-8993(04)01344-7</ArticleId>
<ArticleId IdType="doi">10.1016/j.brainres.2004.08.025</ArticleId>
</ArticleIdList>
</PubmedData>
</pubmed>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001318 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 001318 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Canada
   |area=    ParkinsonCanadaV1
   |flux=    PubMed
   |étape=   Corpus
   |type=    RBID
   |clé=     pubmed:15476704
   |texte=   Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i   -Sk "pubmed:15476704" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd   \
       | NlmPubMed2Wicri -a ParkinsonCanadaV1

This area was generated with Dilib version V0.6.29.
Data generation: Thu May 4 22:20:19 2017. Site generation: Fri Dec 23 23:17:26 2022

	La maladie de Parkinson au Canada (serveur d'exploration)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

La maladie de Parkinson au Canada (serveur d'exploration)

Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.

Preserved ipsilateral-to-lesion motor map organization in the unilateral 6-OHDA-treated rat model of Parkinson's disease.

Source :

English descriptors

Abstract

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri

Pour générer des pages wiki